Taysha Gene Therapies, Inc. Operating Lease, Expense
Taysha Gene Therapies, Inc. (TSHA) reported Operating Lease, Expense of $400.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2022-11-08
- Taysha Gene Therapies, Inc. operating lease, expense for the quarter ending 2022-09-30 was $400.00K, a 300.00% increase year-over-year.
- Taysha Gene Therapies, Inc. operating lease, expense for the quarter ending 2022-06-30 was $300.00K, a 200.00% increase year-over-year.
- Taysha Gene Therapies, Inc. operating lease, expense for the quarter ending 2022-03-31 was $300.00K, a 200.00% increase year-over-year.
- Taysha Gene Therapies, Inc. operating lease, expense for the quarter ending 2021-09-30 was $100.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month |
|---|---|---|---|
| 2022-09-30 | $400.00K 10-Q · filed 2022-11-08 | $700.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.00M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $300.00K 10-Q · filed 2022-08-11 | $600.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $300.00K 10-Q · filed 2022-05-16 | ||
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-08 | $200.00K derived: sum of 2 quarters · filed 2022-11-08 | $100.00K 10-Q · filed 2022-11-08 |
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-11 | $100.00K 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |